CompletedPhase 2

Epinephrine Nasal Drops for Epistaxis During Nasal Intubation

Indonesia40 participantsStarted 2024-01-01

Plain-language summary

Epistaxis is the most common complication of nasotracheal intubation. Incidence of epistaxis during nasotracheal intubation ranges from 22% to 80%. Epistaxis during nasotracheal intubation can lead to several complications such as nasal discomfort, airway obstruction, and blood aspiration. The most commonly used and available topical vasoconstrictor in drop form is oxymetazoline. However, oxymetazoline may not always be available in some hospitals, so epinephrine can be used as an alternative nasal decongestant to reduce the incidence of epistaxis during nasotracheal intubation.

Who can participate

Age range18 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: patients * underwent oral surgery with nasotracheal intubation * aged 18-50 years * ASA (American Society of Anesthesiologists) physical status of 1-2. Exclusion Criteria: * allergy to the medications used * nasal congestion, nasal polyps, allergic rhinitis * hypertension and use of antihypertensive medications, * abnormal coagulation factors, receiving antithrombotic and anticoagulant therapy, * difficult intubation with a LEMON score ≥4, * a history of nasal surgery or nasal trauma, * pregnancy, * heart abnormalities, * ischemic heart disease or arrhythmias, * symptoms of acute respiratory infection perioperatively, * liver and kidney function abnormalities, and * a history of spontaneous epistaxis

What they're measuring

Epistaxis

Timeframe: 2 hour

Trial details

NCT IDNCT06789549

SponsorUniversitas Padjadjaran

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-03-20

View on ClinicalTrials.gov More Oral Surgery trials